Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Current Liabilities (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Total Current Liabilities for 6 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 33.86% year-over-year to $10.7 million, compared with a TTM value of $10.7 million through Dec 2025, up 33.86%, and an annual FY2025 reading of $10.7 million, up 33.86% over the prior year.
  • Total Current Liabilities was $10.7 million for Q4 2025 at SAB Biotherapeutics, down from $10.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $26.5 million in Q4 2021 and bottomed at $80000.0 in Q1 2021.
  • Average Total Current Liabilities over 5 years is $10.7 million, with a median of $10.7 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities surged 23988.3% in 2022, then tumbled 46.14% in 2023.
  • Year by year, Total Current Liabilities stood at $26.5 million in 2021, then crashed by 43.33% to $15.0 million in 2022, then dropped by 27.88% to $10.8 million in 2023, then dropped by 26.21% to $8.0 million in 2024, then surged by 33.86% to $10.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for SABS at $10.7 million in Q4 2025, $10.8 million in Q3 2025, and $10.7 million in Q2 2025.